(Q46570875)

23 December 2017

title

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study (English)

1 reference

23 December 2017

0 references

1 reference

ChEBI release 2020-05-28

9

1 reference

23 December 2017

Grant McArthur

18

1 reference

23 December 2017

Adil Daud

object named as

Adil Daud

6

0 references

Antoni Ribas

1

object named as

Antoni Ribas

1 reference

23 December 2017

5

Thomas F Gajewski

1 reference

23 December 2017

author name string

Rene Gonzalez

2

1 reference

23 December 2017

Anna Pavlick

3

1 reference

23 December 2017

Omid Hamid

4

1 reference

23 December 2017

Lawrence Flaherty

7

1 reference

23 December 2017

Theodore Logan

8

1 reference

23 December 2017

Karl Lewis

10

1 reference

23 December 2017

Damien Kee

11

1 reference

23 December 2017

Peter Boasberg

12

1 reference

23 December 2017

Ming Yin

13

1 reference

23 December 2017

Iris Chan

14

1 reference

23 December 2017

Luna Musib

15

1 reference

23 December 2017

Nicholas Choong

16

1 reference

23 December 2017

Igor Puzanov

17

1 reference

23 December 2017

publication date

15 July 2014

1 reference

23 December 2017

Lancet Oncology Commission

published in

1 reference

23 December 2017

volume

15

1 reference

23 December 2017

page(s)

954-965

1 reference

23 December 2017

issue

9

1 reference

23 December 2017

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Improved survival with MEK inhibition in BRAF-mutated melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970301-8

7 January 2021

10.1016/S1470-2045(14)70301-8

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

25037139

1 reference

23 December 2017